重新定义晚期前列腺癌的激素治疗：LATITUDE和STAMPEDE研究结果 - Suppr | 超能文献

Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.

作者信息

Small Eric J

出版信息

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.009.

DOI:10.1016/j.ccell.2017.08.009

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.重新定义晚期前列腺癌的激素治疗：LATITUDE和STAMPEDE研究结果

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.009.

2

Should docetaxel be administered earlier in prostate cancer therapy?多西他赛是否应在前列腺癌治疗中更早使用？

Expert Rev Anticancer Ther. 2015;15(9):977-9. doi: 10.1586/14737140.2015.1074042. Epub 2015 Jul 29.

3

A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.连续与间歇性雄激素剥夺治疗的回顾：重新定义晚期前列腺癌治疗的金标准。关于“无休止争论”的神话、事实和新数据。

Int Braz J Urol. 2014 Jan-Feb;40(1):3-15; discussion 15. doi: 10.1590/S1677-5538.IBJU.2014.01.02.

4

Medical therapy of prostate cancer. A review.前列腺癌的医学治疗。综述。

Minerva Urol Nefrol. 2005 Jun;57(2):71-84.

5

Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors.局限性和局部晚期前列腺癌的主要激素治疗：有效性和生存预测因素。

Acta Med Indones. 2012 Jan;44(1):10-5.

6

[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease].[三个中心前列腺癌的流行病学及晚期疾病一线激素治疗分析]

Zhonghua Wai Ke Za Zhi. 2008 Jun 15;46(12):921-5.

7

Optimal hormonal therapy for advanced prostatic carcinoma.晚期前列腺癌的最佳激素治疗

Semin Oncol. 1999 Apr;26(2):162-73.

8

Treatment of locally advanced prostate cancer: is chemotherapy the next step?局部晚期前列腺癌的治疗：化疗是下一步的选择吗？

J Clin Oncol. 1999 Nov;17(11):3664-75. doi: 10.1200/JCO.1999.17.11.3664.

9

Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.激素与放射治疗在局部晚期前列腺腺癌中的应用

Semin Radiat Oncol. 2003 Apr;13(2):141-51. doi: 10.1053/srao.2003.50013.

10

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.去势抵抗性前列腺癌的激素药物转换和停药。

Nat Rev Urol. 2015 Jan;12(1):37-47. doi: 10.1038/nrurol.2014.345.

引用本文的文献

1

Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer.抑制清道夫受体B1类（SR-B1）的表达和活性作为破坏去势抵抗性前列腺癌中胆固醇可用性的潜在新靶点。

Pharmaceutics. 2021 Sep 18;13(9):1509. doi: 10.3390/pharmaceutics13091509.

2

Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.转移性前列腺癌患者雄激素剥夺疗法中药物治疗与手术治疗的差异。

Cancer. 2019 Feb 1;125(3):453-462. doi: 10.1002/cncr.31826. Epub 2018 Nov 16.

3

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.一线治疗化疗初治转移性去势抵抗性前列腺癌的安全性和疗效：系统评价和间接比较。

Biomed Res Int. 2017 Dec 7;2017:3941217. doi: 10.1155/2017/3941217. eCollection 2017.